There are better ways to address drug costs than importing socialized medicine 

Currently, Johnson & Johnson, Merck, and Bristol-Myers Squibb are testify Before the Senate Health, Education, Labor and Pensions (HELP) Committee. Hearing what pharmaceutical company executives have to say about drug prices is usually valuable training. But under the proverbial interrogation lamp of HELP Committee Chairman Bernie Sanders (Vt.), the trial will more closely resemble the Salem Witch Trials.

The committee hearing is expected to focus on the price disparity of drugs sold in the United States compared to other countries. Democrats will argue that Americans are paying more at the pharmacy because of “greedy drug companies.” The disparity in drug costs is undoubtedly striking. However, it is naive to slander only pharmaceutical companies.

In some foreign countries, drug prices are manipulated by aggressive government price controls. This is a characteristic of socialized medicine in Europe and our northern neighbors.And patients in these state-run systems pay the price. Access to innovative medicines is limited And because disrupting the free market creates a gap between demand and supply, products are often rationed.

In contrast, Americans have access to some of the most innovative treatments, treatments, and vaccines in the world.

Rather than importing socialist ideas, the committee’s time would be better spent promoting existing policy proposals that address inflationary pressures in health care while keeping the innovation pipeline intact. The key is to encourage more competition. Targeting the bloat caused by an anti-competitive environment is a step in the right direction. And it’s an idea that has bipartisan support.

Currently, the pharmaceutical supply chain is dominated by three intermediaries called pharmacy benefit managers (PBMs). 80 percent of the prescription drug market. These organizations are the gatekeepers between the pharmaceutical production line and the consumer. And the lack of competition means these three giants enjoy significant leverage to drive up healthcare costs for patients.

Policy proposals already before Congress would help curb the suspicious practices of unscrupulous apple brokers, lower drug costs for patients, and open up the industry to more competition.There is dozens of Other smaller PBMs can help control prices if they are provided with a level playing field.

The Cost Reduction and Transparency Act is a law that: passed it By the end of 2023, the House of Commons will shine a spotlight on pharmaceutical supply chains, ensuring transparency that can help reduce costs. Meanwhile, other bills aim at adverse incentives within his PBM business model at scale.

In the current system, dominant intermediaries make significant profits from more expensive medicines and therefore tend to push their products onto patients. Its size means great potential. Manipulate Pattern prescribed by a doctor.Proposals like the Unlinking Proceeds from Unwarranted Gouging Act would help reset motivation This is to encourage more affordable and popular alternatives.

HELP committee hearings are unlikely to advance constructive policies that effectively reduce drug costs for Americans without causing consequences similar to those associated with European-style socialized medicine. Instead, lawmakers should advance existing bipartisan proposals that target backward incentives and promote patient choice within the drug supply chain.

Dr. Tom Price is the 23rd U.S. Secretary of Health and Human Services and a senior health policy fellow at Job Creators Network. Elaine Parker is Chair of the Job Creator Network Foundation. HealthcareForYou.com Framework for policy reform.